Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$26850.00
-600.00 (-2.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $37.1B · quality 80.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$276.2B
P/E
5.4x
↓EV/EBITDA
3.2x
↓ROE
17.3%
↑Gross Margin
46.8%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.3%
FCF CAGR
+6.3%
FCF margin
21.8%
FCF / Net income
0.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $170.05B · net income $51.79B · FCF $37.13B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $170.05B | $170.05B | $161.87B | $152.27B | $123.17B |
| Net Income | $51.79B | $51.79B | $39.26B | $24.82B | $21.09B |
| EBITDA | $74.79B | $74.79B | $59.88B | $45.13B | $43.65B |
| EPS | 5007.00 | 5007.00 | 3795.00 | 2512.00 | 2274.00 |
| Gross Margin | 46.8% | 46.8% | 46.3% | 46.2% | 44.4% |
| Operating Margin | 24.9% | 24.9% | 26.7% | 24.5% | 21.1% |
| Net Margin | 30.5% | 30.5% | 24.3% | 16.3% | 17.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.26 |
| Current Ratio | 3.06 | 3.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $37.13B | $37.13B | $42.08B | $21.86B | $30.87B |
| Returns | |||||
| ROE | 17.3% | 17.3% | 17.2% | 12.5% | 15.2% |
| Valuation | |||||
| P/E | 5.36 | 5.36 | 10.62 | 12.50 | 12.05 |
| EV/EBITDA | 3.20 | 3.20 | 5.17 | 5.16 | 4.56 |
| P/B | 0.93 | 0.93 | 1.82 | 1.57 | 1.83 |
| Growth & Yield | |||||
| Revenue Growth | 5.1% | 5.1% | 6.3% | 23.6% | — |
| EPS Growth | 31.9% | 31.9% | 51.1% | 10.5% | — |
| Dividend Yield | 4.2% | 4.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-21.9%
EPS terminal req.
$2382.49
Spread vs growth
53.9%
5Y implied EPS CAGR
-10.5%
EPS terminal req.
$2882.81
Spread vs growth
42.4%
10Y implied EPS CAGR
-0.8%
EPS terminal req.
$4642.80
Spread vs growth
32.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.6%
Start / end P/E
11.0x → 5.4x
EPS bridge
3795.00 → 5007.00
Residual
-16.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.